ASTRAZENECA PLC — All Filings
1,000 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
11-K
144
20-F
20-F/A
25
25-NSE
3
3/A
4
424B2
424B3
424B5
425
6-K
6-K/A
8-A12B
8-A12B/A
CERT
CERTNYS
CORRESP
CT ORDER
DFAN14A
EFFECT
F-3
F-3ASR
F-4
F-4/A
F-6
F-6 POS
F-6EF
FWP
IRANNOTICE
NO ACT
S-1
S-8
S-8 POS
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SC TO-C
SC TO-T
SC TO-T/A
SCHEDULE 13D/A
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 6-K | TOTAL VOTING RIGHTS | 0001654954-25-013567 | Dec 1, 2025 | — |
| 6-K | IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER | 0001654954-25-013450 | Nov 26, 2025 | — |
| 6-K | ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND | 0001654954-25-013401 | Nov 24, 2025 | — |
| 6-K | KOSELUGO (SELUMETINIB) APPROVED IN THE US | 0001654954-25-013317 | Nov 20, 2025 | — |
| 6-K | HOLDING(S) IN COMPANY | 0001654954-25-013129 | Nov 17, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-013043 | Nov 14, 2025 | — |
| 25-NSE | — | 0001354457-25-001137 | Nov 14, 2025 | — |
| 144 | — | 0001950047-25-008803 | Nov 12, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-012757 | Nov 10, 2025 | — |
| 6-K | 9M AND Q3 2025 RESULTS | 0001654954-25-012630 | Nov 6, 2025 | — |
| 6-K | FORM 6-K | 0001104659-25-105425 | Nov 3, 2025 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-25-012498 | Nov 3, 2025 | — |
| 6-K | RESULT OF GENERAL MEETING | 0001654954-25-012502 | Nov 3, 2025 | — |
| 6-K | DIRECTOR DECLARATION | 0001654954-25-012271 | Oct 28, 2025 | — |
| 6-K | KOSELUGO (SELUMETINIB) APPROVED IN THE EU | 0001654954-25-012262 | Oct 28, 2025 | — |
| 6-K | TEZSPIRE APPROVED IN EU FOR CRSWNP | 0001654954-25-012040 | Oct 22, 2025 | — |
| 6-K | POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO | 0001654954-25-011943 | Oct 20, 2025 | — |
| 6-K | US FDA APPROVES TEZSPIRE IN CRSWNP | 0001654954-25-011951 | Oct 20, 2025 | — |
| 6-K | AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES | 0001654954-25-011688 | Oct 14, 2025 | — |
| 6-K | BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL | 0001654954-25-011529 | Oct 7, 2025 | — |
| 6-K | DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02 | 0001654954-25-011461 | Oct 6, 2025 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-25-011310 | Oct 1, 2025 | — |
| 6-K | ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05 | 0001654954-25-011177 | Sep 29, 2025 | — |
| 6-K | 6-K | 0001104659-25-094039 | Sep 29, 2025 | — |
| 6-K | AZN HARMONISES LISTING STRUCTURE | 0001654954-25-011175 | Sep 29, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-011107 | Sep 25, 2025 | — |
| 6-K | TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP | 0001654954-25-010967 | Sep 22, 2025 | — |
| 6-K | KOSELUGO RECOMMENDED FOR EU APPROVAL | 0001654954-25-010969 | Sep 22, 2025 | — |
| 6-K | UPDATE ON RESOLUTE PHASE III TRIAL | 0001654954-25-010845 | Sep 17, 2025 | — |
| 6-K | SAPHNELO MET PRIMARY ENDPOINT IN TULIP-SC | 0001654954-25-010847 | Sep 17, 2025 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-25-010235 | Sep 2, 2025 | — |
| 6-K | HOLDING(S) IN COMPANY | 0001654954-25-010131 | Aug 28, 2025 | — |
| 6-K | HOLDING(S) IN COMPANY | 0001654954-25-010040 | Aug 26, 2025 | — |
| 6-K | HOLDING(S) IN COMPANY | 0001654954-25-009884 | Aug 21, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-009748 | Aug 18, 2025 | — |
| 6-K | HOLDING(S) IN COMPANY | 0001654954-25-009692 | Aug 15, 2025 | — |
| 6-K | HOLDING(S) IN COMPANY | 0001654954-25-009396 | Aug 12, 2025 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-25-008838 | Aug 1, 2025 | — |
| 6-K | FORM 6-K | 0001104659-25-071432 | Jul 29, 2025 | Jun 30, 2025 |
| 6-K | GEFURULIMAB NANOBODY MET PHASE III ENDPOINTS | 0001654954-25-008413 | Jul 24, 2025 | — |
| 6-K | ASTRAZENECA PLANS TO INVEST $50BN IN THE US | 0001654954-25-008260 | Jul 22, 2025 | — |
| 6-K | UPDATE ON ANSELAMIMAB IN AL AMYLOIDOSIS | 0001654954-25-008111 | Jul 16, 2025 | — |
| 6-K | BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIAL | 0001654954-25-008010 | Jul 14, 2025 | — |
| 6-K | IMFINZI APPROVED IN THE EU FOR BLADDER CANCER | 0001654954-25-007785 | Jul 7, 2025 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-25-007604 | Jul 1, 2025 | — |
| 11-K | FORM 11-K | 0001683168-25-004771 | Jun 26, 2025 | Dec 31, 2024 |
| 6-K | DATROWAY APPROVED IN US FOR EGFRM LUNG CANCER | 0001654954-25-007315 | Jun 24, 2025 | — |
| 6-K | ASTRAZENECA ENTERS INTO COLLABORATION WITH CSPC | 0001654954-25-006914 | Jun 13, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-006868 | Jun 12, 2025 | — |
| 6-K | FIXED-DURATION CALQUENCE APPROVED IN EU FOR 1L CLL | 0001654954-25-006655 | Jun 6, 2025 | — |